Full-Time
Senior Statistical Programmer
Rhythm Pharmaceuticals
201-500 employees
Commercializes MC4R-targeted therapies for rare obesity
Compensation Overview
$90k - $135k/yr
Boston, MA, USA
Hybrid
Hybrid work requires attendance at the Boston office based on department and business needs.
Master's
 Biology & Biotech (1) |
|---|
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
- A Master of Science or equivalent degree in Statistics, Biostatistics, Mathematics, Computer Science, or a related discipline is required.
- At least 3 years of relevant statistical programming experience in biotech, pharmaceutical, or contract research organization settings is required.
- Strong hands-on expertise in Statistical Analysis System programming, including Base SAS, SAS/STAT, SAS/GRAPH, SAS/SQL, SAS/ODS, and macro development, is required.
- Deep knowledge of Clinical Data Interchange Standards Consortium standards, including SDTM, ADaM, define.xml, reviewer guides, and electronic submission requirements in electronic Common Technical Document format, is required.
- Experience supporting study-level and integrated analyses, including ISS/ISE or other cross-study deliverables, is required.
- Strong understanding of clinical trial reporting and regulatory submission processes is required.
- The candidate must be able to work independently, manage priorities, collaborate cross-functionally, and deliver high-quality work in a fast-paced environment.
- Lead or support statistical programming activities for assigned clinical studies, including development, validation, and quality control of analysis datasets, tables, listings, and figures for study reports, regulatory submissions, and internal decision-making.
- Serve as a study lead programmer or programming representative, partnering with Biostatistics, Data Management, Clinical Development, Medical Writing, Regulatory, and external vendors to deliver high-quality results on time.
- Develop, review, and maintain ADaM specifications, TLF shells, programming documentation, reusable macros, and study-level programming standards in alignment with company procedures and regulatory expectations.
- Provide input into protocols, statistical analysis plans, CRF design and annotation, edit checks, SDTM specifications, integrated data review, and submission strategy to ensure traceability, consistency, and efficient downstream analysis.
- Support regulatory submission readiness, including preparation and review of define.xml, reviewer guides, submission-ready datasets, and related documentation in compliance with CDISC and global regulatory requirements.
- Identify programming risks, drive issue resolution, and recommend process improvements that enhance quality, scalability, efficiency, and inspection readiness across studies and programs.
- An advanced degree is preferred.
- Experience with R or other modern programming tools is a plus.
- Vendor oversight experience is preferred but not required.
- Depending on level, experience mentoring junior programmers, providing technical guidance, contributing to resource planning, overseeing external vendor deliverables, and contributing to process improvement is a plus.
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine and genetic obesity disorders. Its lead drug, IMCIVREE (setmelanotide), is an MC4R agonist that helps restore signaling in the melanocortin-4 pathway to regulate hunger and energy use. The company earns revenue primarily from global IMCIVREE sales and reinvests in research, development, and commercialization. Its aim is to broaden MC4R-targeted treatments for underserved patients and advance additional candidates like bivamelagon and RM-718 through clinical development.
Company Size
201-500
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
2008
Get referred to Rhythm Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 IMCIVREE revenue reached $71.3 million, up 47% year over year.
- More than 400 acquired-HO start forms arrived by June 30, 2026, signaling strong demand.
- Japan approved acquired-HO IMCIVREE in August 2026, with launch targeted before year-end.
What critics are saying
- March 2026 Phase 3 genetic-obesity failure blocks label expansion beyond current narrow indications.
- Rhythm depends heavily on IMCIVREE; any launch stumble in Japan hits 2026 growth.
- Next-generation MC4R drugs still need proof; RM-718's 11-patient dataset leaves an existential gap.
What makes Rhythm Pharmaceuticals unique
- IMCIVREE is first approved therapy for acquired hypothalamic obesity in the US, Europe, Japan.
- Rhythm owns the MC4R obesity franchise, spanning setmelanotide, RM-718, and bivamelagon.
- Rare-disease genetics and diagnostic algorithms create defensible physician relationships beyond pure commercial advertising.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 8%2 year growth
↑ 2%Rhythm Pharmaceuticals has received approval from Japan's Ministry of Health, Labour and Welfare for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO). This marks the first therapy approved in Japan for this condition. The approval was supported by the Phase 3 TRANSCEND trial involving 142 patients, including a Japanese cohort. The study met its primary endpoint with an 18.8% placebo-adjusted reduction in body mass index. Rhythm estimates 5,000 to 8,000 people are living with acquired HO in Japan. The company expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Acquired HO is characterised by accelerated weight gain following hypothalamic injury, often resulting from craniopharyngioma, astrocytoma, or other hypothalamic-pituitary tumours.
Rhythm Pharmaceuticals has appointed Manher "AJ" Joshi as Chief Medical Officer, effective 17 August. Dr Joshi brings over 20 years of experience spanning drug discovery, pivotal trials, regulatory processes and lifecycle management. Dr Joshi joins from Soleno Therapeutics, where he served as Chief Development Officer. He previously held the Chief Medical Officer position at Neurona Therapeutics and executive roles at Atara Biotherapeutics. His career also includes leadership positions at Allergan Medical, Synageva BioPharma, and Genzyme. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), is approved in the US and Europe for treating certain forms of obesity. The company is advancing next-generation MC4R agonists through late-stage development.
Rhythm Pharmaceuticals announced that the UK's Medicines and Healthcare products Regulatory Agency has expanded the marketing authorisation for IMCIVREE (setmelanotide) to include treatment of obesity and control of hunger in adults and children aged 4 and older with acquired hypothalamic obesity due to hypothalamic injury or impairment. The MHRA also granted IMCIVREE orphan drug designation for acquired HO. The approval is based on results from the Phase 3 TRANSCEND trial, which met its primary endpoint with a statistically significant 19.8% placebo-adjusted reduction in body mass index. The global trial enrolled 120 patients. IMCIVREE initially received marketing authorisation in the UK in 2021 for treatment of obesity in patients with POMC, PCSK1 or LEPR deficiency, with subsequent expansions for other rare obesity conditions.
Rhythm Pharmaceuticals reported preliminary results showing its experimental weekly injectable drug RM-718 helped reduce body weight in patients with acquired hypothalamic obesity, a rare condition caused by brain damage from tumour surgery or treatment. The Boston-based company's shares rose 5% in premarket trading. Among 11 enrolled patients, seven who completed 16 weeks of treatment saw their body mass index fall by an average of 11.6%. The drug works by activating the MC4R brain receptor, which controls hunger and metabolism. Two patients discontinued treatment due to side effects including nausea and injection site problems. Rhythm also sells setmelanotide for the same condition under the brand name Imcivree. Separately, the company reported second-quarter revenue of $71.3 million, up 46.9% from $48.5 million a year earlier.
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE, marking a 19% sequential increase from the first quarter. The company received over 400 patient start forms for IMCIVREE's acquired hypothalamic obesity indication from approximately 300 prescribers as of 30 June 2026, following FDA approval in March. US revenue reached $51.0 million, representing 72% of product revenue and a 38% sequential increase, driven primarily by acquired hypothalamic obesity demand. The company reported preliminary Phase 2 data showing weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in acquired hypothalamic obesity patients after 16 weeks. Cash, cash equivalents, and short-term investments totalled approximately $330.9 million as of 30 June 2026. The company posted a net loss of $50.4 million for the quarter.